ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Remus delivered strong H1 growth led by international operations, though consolidated margins are skewed by a low-margin US distribution transaction.
H1-FY27 consolidated revenue INR 6,141 Mn (+53.4%) and PAT INR 247 Mn (+14.4%), with EBITDA margin compressing to 4.87%. Standalone PAT rose 56.7%. Growth comes from tender wins and LATAM/SEA expansion.
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Remus Pharmaceuticals has fixed 7 November 2026 as the record date for its 1st interim dividend for FY 2026-27, declared at today's board meeting. The filing does not state the per-share dividend amount.
Remus Pharmaceuticals Ltd reported revenue from operations of ₹614.1 Cr (+53.4% YoY) and net profit of ₹24.7 Cr (+14.4% YoY) for H1 FY27.
Remus Pharmaceuticals filed its Reg 76 Reconciliation of Share Capital Audit Report for Q1 FY2027. It is a routine depository-compliance certificate with no transaction or business event.
Remus Pharmaceuticals Limited shareholders approved the migration of equity shares from the NSE Emerge platform to the main boards of NSE and BSE.
Remus Pharmaceuticals held its 11th Annual General Meeting on September 29, 2026. Shareholders discussed financial results, dividend declaration, and director appointments.
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.
Remus Pharmaceuticals delivered high double-digit revenue growth in H2FY26, driven by aggressive international B2C expansion in Latin America and new specialized therapy launches.
Remus Pharmaceuticals reported FY26 consolidated revenue of ₹8,536 Mn, representing 37.6% growth. The company maintains an asset-light model focusing on complex specialty formulations in semi-regulated markets.
Remus Pharmaceuticals appointed Mr. Tapan Shah as Secretarial Auditor for FY 2026-2027. The appointment follows recommendation by the Audit Committee and Board approval.
Remus Pharmaceuticals reported FY26 revenue of ₹853.63 Crore, a 37.6% YoY increase. Strong growth in its B2C entity Relius drove exceptional financial performance and expansion.
Remus Pharmaceuticals recommended a final dividend of Rs. 0.50 per equity share for 2026. The record date will be announced later following shareholder approval.
Remus Pharmaceuticals Ltd reported revenue from operations of ₹453.4 Cr (+30.4% YoY) and net profit of ₹24.6 Cr (+19.4% YoY) for H2 FY26.
Remus Pharmaceuticals reported FY26 consolidated revenue of ₹853.63 Crore and PAT of ₹46.17 Crore. The board recommended a final dividend of ₹0.50 per share.
Remus Pharmaceuticals scheduled a board meeting for May 20, 2026, to approve audited annual financial results and a final dividend. Trading window remains closed until May 22.